All In Biotech

Drug Trial Radar · NCT07560124

A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer

A Phase Ib/II Study of AK138D1 as Monotherapy and in Combination With Ivonescimab in Patients With Advanced Breast Cancer

Last checked: Nov 19, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 286 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

286

Planned (sponsor's estimate)

Start

Jun 6, 2026

Primary completion

Jun 6, 2028

Study completion Sep 14, 2030

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Apr 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of AK138D1 as monotherapy or in combination with ivonescimab in patients with advanced breast cancer. Participants will receive study treatment with AK138D1 alone or in combination with ivonescimab, undergo safety assessments and tumor evaluations, and be followed for treatment tolerability, antitumor activity, and clinical outcomes.

Conditions

  • Breast Cancer

Interventions

  • AK138D1Drug

    Enrolled subjects will receive intravenous infusion (IV) of AK138D1 according to the dosing regimen specified in their cohort.

  • IvonescimabDrug

    Enrolled subjects will receive intravenous infusion (IV) of ivonescimab according to the dosing regimen specified in their cohort.

  • treatment of physician's choiceDrug

    Enrolled subjects will receive treatment of physician's choice according to one of the protocol-specified regimens selected by the investigator, based on the investigator's decision.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events (AEs)Time frame: Up to approximately 2 years
  2. Overall Response Rate (ORR) assessed by investigator per RECIST v1.1Time frame: Up to approximately 2 years

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.